The ART of tumor immune escape

We recently identified the adenosine-5′-diphosphate (ADP)–ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD(+)) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wennerberg, Erik, Mukherjee, Sumit, Sainz, Ricardo M., Stiles, Brendon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116389/
https://www.ncbi.nlm.nih.gov/pubmed/35602287
http://dx.doi.org/10.1080/2162402X.2022.2076310
Descripción
Sumario:We recently identified the adenosine-5′-diphosphate (ADP)–ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD(+)) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) on CD8 T cells, resulting in NAD-induced cell death (NICD) and tumor immune resistance. This process is blocked by therapeutic antibody targeting of ART1.

Ejemplares similares